title: Significance of estrogen receptor 1 (ESR-1) gene imbalances in colon and hepatocellular carcinomas based on tissue microarrays analysis.
abstract: Estrogen receptor alpha-encoded by ESR1 gene-overexpression correlates with prognosis and response to specific chemotherapy in breast adenocarcinoma cases. Mechanisms of ESR-1 deregulation in carcinomas remain under investigation. To analyze ESR1 in carcinomas of different histogenesis. Using tissue microarray technology, 172 primary carcinomas including breast ductal adenocarcinomas (n=60), hepatocellular carcinomas (n=52), and colon adenocarcinomas (n=60) were cored and re-embedded in three paraffin blocks. Initial diagnosis was based on liquid based cytology (LiquiPrep/ThinPrep). Immunohistochemistry and fluorescence in situ hybridization were performed. Quantitative evaluation of ER-a protein levels was assessed by applying digital image analysis. ER-a overexpression was observed in 41/60 (68.3%), 23/52 (44.2%) and 4/60 (6.6%) cases, respectively. ESR1 gene multiple copies were confirmed in 13/60 (21.6%) breast adenocarcinomas, but high amplification only in 8/13 (62.8%). Allelic absence was identified in 3/52 (5.7%) hepatocellular carcinomas, whereas colon adenocarcinomas demonstrated gene gains in 5/60 (8.3%) cases referred to chr 6 aneuploidy and not to amplification. ER-a overall expression was associated strongly to ESR1 gene copies only in breast carcinoma (P=0.036). ESR-1 gene overexpression happens frequently in breast cancer, but only a subset of them are high amplified cases correlated to increased response rates in hormonal therapy (tamoxifen). Absence of this mechanism in hepatocellular and colon carcinomas maybe is a negative factor for applying this therapy. This is a pattern of histo-genetic depended targeted therapeutic strategy.
authors.affiliation: Department of Pathology, Medical School, University of Athens, and Department of Breast Cancer Surgery, Blue Cross Hospital, str Patriarchou Grigoriou E 17 Ag Paraskevi Attiki, 15341, Athens, Greece. tsiambasecyto@yahoo.gr
authors.forename: Evangelos
authors.initials: E
authors.lastname: Tsiambas
authors.forename: Stavros N
authors.initials: SN
authors.lastname: Georgiannos
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Salemis
authors.forename: Despoina
authors.initials: D
authors.lastname: Alexopoulou
authors.forename: Sofia
authors.initials: S
authors.lastname: Lambropoulou
authors.forename: Blerta
authors.initials: B
authors.lastname: Dimo
authors.forename: Ioannis
authors.initials: I
authors.lastname: Ioannidis
authors.forename: Christos
authors.initials: C
authors.lastname: Kravvaritis
authors.forename: Andreas
authors.initials: A
authors.lastname: Karameris
authors.forename: Efstratios
authors.initials: E
authors.lastname: Patsouris
authors.forename: Spyridon
authors.initials: S
authors.lastname: Dourakis
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics*; D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology; D006528:Carcinoma, Hepatocellular / Q000235:genetics* / Q000473:pathology; D003110:Colonic Neoplasms / Q000235:genetics* / Q000473:pathology; D047628:Estrogen Receptor alpha / Q000235:genetics*; D005260:Female; D005784:Gene Amplification; D020869:Gene Expression Profiling; D006801:Humans; D007090:Image Interpretation, Computer-Assisted; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D008113:Liver Neoplasms / Q000235:genetics* / Q000473:pathology; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D046888:Tissue Array Analysis
chemical_list: C506487:ESR1 protein, human; D047628:Estrogen Receptor alpha
references.citation: Am J Pathol. 2000 Aug;157(2):689
references.pmid: 10934171
references.citation: J Clin Pathol. 2008 Jan;61(1):68-71
references.pmid: 17412872
references.citation: Gastroenterology. 2006 Jun;130(7):2001-9
references.pmid: 16762623
references.citation: Endocr Relat Cancer. 2008 Dec;15(4):985-1002
references.pmid: 18824559
references.citation: Nat Genet. 2008 Jul;40(7):809; author reply 810-2
references.pmid: 18583967
references.citation: Biochem Biophys Res Commun. 1997 Nov 17;240(2):464-70
references.pmid: 9388502
references.citation: Cancer Genet Cytogenet. 2000 Jan 1;116(1):23-7
references.pmid: 10616527
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3621-7
references.pmid: 19064581
references.citation: Am J Surg. 2009 Oct;198(4):520-5
references.pmid: 19800460
references.citation: J Clin Oncol. 2009 Aug 20;27(24):3881-6
references.pmid: 19620488
references.citation: Nat Genet. 2008 Jul;40(7):821-2
references.pmid: 18583976
references.citation: J Surg Oncol Suppl. 1993;3:14-7
references.pmid: 8389161
references.citation: Nat Genet. 2007 May;39(5):655-60
references.pmid: 17417639
references.citation: J Clin Oncol. 2005 Mar 10;23(8):1616-22
references.pmid: 15755967
references.citation: Mol Cell Endocrinol. 2002 Jul 31;193(1-2):65-9
references.pmid: 12161003
references.citation: Nat Genet. 2003 Aug;34(4):369-76
references.pmid: 12923544
references.citation: Carcinogenesis. 2004 Aug;25(8):1345-57
references.pmid: 15001537
references.citation: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references.pmid: 15761078
references.citation: Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12963-8
references.pmid: 12297621
references.citation: J Urol. 2005 Oct;174(4 Pt 2):1695-8; discussion 1698
references.pmid: 16148684
references.citation: J Hepatol. 1993 Feb;17(2):187-91
references.pmid: 8383159
references.citation: Steroids. 1991 May;56(5):263-70
references.pmid: 1877066
references.citation: J Clin Oncol. 2008 Dec 10;26(35):5697-704
references.pmid: 19001334
references.citation: Cancer Genet Cytogenet. 2003 Jul 1;144(1):23-30
references.pmid: 12810252
references.citation: Drug News Perspect. 2009 Mar;22(2):93-106
references.pmid: 19330168